Subtypes of basal cell carcinoma, the most common type of skin cancer, may differ in appearance, aggressiveness, treatment options, and who’s likely to develop them. Basal cell carcinoma (BCC) is the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Five years after treatment, results showed a freedom ...
In a randomized trial, recurrence was higher after superficial curettage (SC) plus imiquimod cream than surgical excision (SE) in patients with nodular basal cell carcinoma (nBCC). At 5 years ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The first patient has been enrolled in a phase 2 trial ...
Basal cell carcinoma is the most common skin cancer, often caused by UV exposure, and originates in the epidermis's basal cells. Diagnosis involves clinical examination and biopsy to confirm BCC and ...
The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) The Company also announced that it is ...
--Medicus Pharma Ltd., a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that its ...
Medicus Pharma reports over 50% patient enrollment in Phase 2 study for basal cell carcinoma treatment, aiming for FDA fast-track approval. Medicus Pharma Ltd. announced that over 50% of the 60 ...
THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results